(function(){ var content_array=["

关于 Gene Solutions<\/b><\/p> \n

Gene Solutions 是一家亚洲跨国生物科技公司，在利用先进的人工智能 (AI) 和 ctDNA 技术提供创新癌症检测解决方案方面处于领先地位。公司与东南亚 4,500 多家医院和诊所合作，拥有一支由约 250 名生物学专家和技术人员组成的专业团队，员工总数达 700 人。<\/p> \n

Gene Solutions 已在东南亚地区发表了 50 多篇同行评审的论文，并开展了 50 多项多中心研究，其自主研发成果以及位于新加坡和越南的 CAP 认证的新一代测序 (NGS) 实验室备受认可。通过将多维基因组学与人工智能驱动的方法相结合，公司致力于变革癌症治疗，令更多癌症患者受益。<\/p> \n

    \n
  1. Hoang, V.-A.N. et al. (2025) 'Real-World utilization and performance of circulating tumor DNA monitoring to predict recurrence in solid tumors,' JCO Oncology Advances, Volume 2. DOI: 10.1200\/OA-24-00084<\/span><\/li> \n
  2. Huang, J. et al. (2022) 'Cancer incidence and mortality in Asian countries: a trend analysis,' Cancer Control, 29. DOI:10.1177\/10732748221095955.<\/span><\/li> \n
  3. Sharma, R. et al. (2024) 'Temporal patterns of cancer burden in Asia<\/span>, 1990-2019: a systematic examination for the Global Burden of Disease 2019 study,' The Lancet Regional Health - Southeast Asia<\/span>, 21, p. 100333. DOI:10.1016\/j.lansea.2023.100333.<\/span><\/li> \n
  4. Kobayashi, S. et al. (2025) 'Japan<\/span> society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing,' International Journal of Clinical Oncology [Preprint]. DOI:10.1007\/s10147-024-02683-0.<\/span><\/li> \n
  5. Use of Circulating Tumor DNA for Curative-Intent Solid Tumor Drug Development. (2024). In Guidance for Industry [Clinical\/Medical]. FDA Guidances, Content current as of: 01\/17\/2025.<\/span><\/li> \n<\/ol> \n
    \n<\/div>"]; $("#dvExtra").html(content_array[0]);})();